After a challenging selection process and a highly competitive pitch contest, five science start-ups were awarded £20k and access to the Babraham Research Campus’ bio-incubator facilities, Accelerate@Babraham. In addition, a spin-out from the Babraham Institute, SNPr was invited to attend the programme. We caught up with three of the winning ventures - Antiverse, Kalium Diagnostics and Visusnano - towards the end of the programme to find out what how their ventures have progressed during their time on Campus, what they found most valuable about the Accelerate@Babraham programme and where they see themselves in 12 months time.
Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day.
Co-founder Dr Rowina Westermeier has a PhD in Biochemistry from the University of Cambridge in cell-free protein synthesis and is using this cutting-edge technique for the high-throughput generation of antibody fragments. She previously worked as a protein synthesis scientist for drug development for the contract research organisation Domainex.
We sat down with Rowina to talk about why she entered the competition, what impact it’s had and what’s next for Antiverse.
Kalium Diagnostics uses blood potassium monitoring to help kidney patients monitor their blood potassium levels and thereby reduce total healthcare costs. The venture, spun out of the University of Cambridge, brings together a team with world-class clinical, technological and product development expertise.
We caught up with two of Kalium’s Co-Founders Tanya Hutter and Liz Norgett to see how winning the Accelerate@Babraham Start-up Competition has helped them to progress their work.
VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, the project has the potential to revolutionise cataract surgery in both the human and veterinary markets.
We spoke to VisusNano’s CEO, Joanna Gould, about her time on the Accelerate@Babraham programme and what the next steps are for the company.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557